news

  • 26 June 2019
    InDex Pharmaceuticals gets new patent in Europe

    InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.

    The patent, entitled Method for prevention of colectomy (patent number EP2782602), will provide an exclusivity period until November 2032, with the possibility of up to 5 years term extension after market approval.

    “This new patent constitutes a valuable complement to our robust intellectual property portfolio for cobitolimod in Europe,” said Peter Zerhouni, CEO of InDex Pharmaceuticals.

    Corresponding patent applications were granted in the US in November 2016 and in Japan in August 2017, and a corresponding patent application has been filed in Canada.